Dianthus Therapeutics logo

Dianthus Therapeutics

DNTH | NASDAQ
Chart Builder DCF Calculator
$89.55
-$2.26 (-2.46%)
At close: Nov 16, 2026, 4:00 PM ET
$89.02
-$0.53 (-0.59%)
After-hours: Nov 16, 2026, 7:51 PM ET
-2.46%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
41.7
Fundamentals Average
Market Sentiment Bullish
Moat None
Sector Rank #476/1021 (Top 47%)

Key Statistics

Market Data

Market Cap $5.04B
1D Range
87.85 93.81
52W Range
36.20 115.96

Valuation (TTM)

PE -
PB 4.06
EV/EBITDA -106.76

Valuation (NTM)

Forward PE N/A
Forward PEG -774.28
Price Target $133.00
Loading financial charts...

Profile

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, clasepruba...

Sector Healthcare
Industry Biotechnology
Employees 92
IPO Date Jun 21, 2018
Fiscal Year January - December

Latest News

Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript

17 hours ago · seekingalpha.com

Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript
Wall Street Analysts See a 61.23% Upside in Dianthus Therapeutics, Inc. (DNTH): Can the Stock Really Move This High?

8 days ago · zacks.com

Wall Street Analysts See a 61.23% Upside in Dianthus Therapeutics, Inc. (DNTH): Can the Stock Really Move This High?
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates

12 days ago · zacks.com

Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates
Dianthus Therapeutics to Participate in Five Investor Conferences During November

14 days ago · globenewswire.com

Dianthus Therapeutics to Participate in Five Investor Conferences During November
Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharma

1 month ago · globenewswire.com

Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharma
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting

2 months ago · globenewswire.com

Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

2 months ago · seekingalpha.com

Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Dianthus Therapeutics to Participate in Three Investor Conferences During September

3 months ago · globenewswire.com

Dianthus Therapeutics to Participate in Three Investor Conferences During September
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case

3 months ago · seekingalpha.com

Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

3 months ago · zacks.com

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

Earnings

Latest Earnings
Nov 4, 2026
EPS
-$0.81
Beat +14.24%
REV
$1.21M
Beat +162.51%
Next Earnings
Mar 8, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
10
Consensus
Buy
Price Target
$133.00
Upside
+48.52%
Buy (10)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.